SB-243213

Summary

SB-243213 is a research chemical which acts as a selective inverse agonist for the 5HT2C receptor and has anxiolytic effects. It has better than 100x selectivity for 5-HT2C over all other receptor subtypes tested, and a longer duration of action compared to older 5-HT2C antagonist ligands.[1][2][3][4][5][6][7][8]

SB-243213
Identifiers
  • 5-methyl-N-(6-[(2-methylpyridin-3-yl)oxy]pyridin-3-yl)-6-(trifluoromethyl)indoline-1-carboxamide
CAS Number
  • 200940-23-4
PubChem CID
  • 443391
ChemSpider
  • 391620
UNII
  • PA86JD65ZJ
CompTox Dashboard (EPA)
  • DTXSID0047323 Edit this at Wikidata
Chemical and physical data
FormulaC22H19F3N4O2
Molar mass428.415 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC1=C(C(F)(F)F)C=C(N(C(NC2=CN=C(OC3=C(C)N=CC=C3)C=C2)=O)CC4)C4=C1
  • InChI=1S/C22H19F3N4O2/c1-13-10-15-7-9-29(18(15)11-17(13)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-19-4-3-8-26-14(19)2/h3-6,8,10-12H,7,9H2,1-2H3,(H,28,30)
  • Key:ZETBBVYSBABLHL-UHFFFAOYSA-N

See also edit

References edit

  1. ^ Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, et al. (August 2001). "SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety". Neuropharmacology. 41 (2): 186–99. doi:10.1016/S0028-3908(01)00054-5. PMID 11489455. S2CID 36124035.
  2. ^ Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR (December 2002). "Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study". Synapse. 46 (3): 129–39. doi:10.1002/syn.10116. PMID 12325040. S2CID 36766760.
  3. ^ Di Matteo V, Pierucci M, Esposito E (April 2004). "Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration". Journal of Neurochemistry. 89 (2): 418–29. doi:10.1111/j.1471-4159.2004.02337.x. PMID 15056285. S2CID 29021463.
  4. ^ Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–58. doi:10.1007/s00213-004-1962-z. PMID 15289999. S2CID 20866665.
  5. ^ Berg KA, Navailles S, Sanchez TA, Silva YM, Wood MD, Spampinato U, Clarke WP (October 2006). "Differential effects of 5-methyl-1-2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses". The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 260–8. doi:10.1124/jpet.106.104448. PMID 16807362. S2CID 14889900.
  6. ^ Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID 17059817.
  7. ^ Leggio GM, Cathala A, Moison D, Cunningham KA, Piazza PV, Spampinato U (February 2009). "Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens". Neuropharmacology. 56 (2): 507–13. doi:10.1016/j.neuropharm.2008.10.005. PMC 3130963. PMID 18977370.
  8. ^ Kadiri N, Lagière M, Le Moine C, Millan MJ, De Deurwaerdère P, Navailles S (August 2012). "Diverse effects of 5-HT2C receptor blocking agents on c-Fos expression in the rat basal ganglia". European Journal of Pharmacology. 689 (1–3): 8–16. doi:10.1016/j.ejphar.2012.05.022. PMID 22643326.